ClinicalTrials.gg
CompletedNCT05173818HOINPCSUpdated Oct 15, 2026Results posted

Hyperbaric Oxygen Effects on Persistent Post-concussive Symptoms

A Phase 2 interventional study of Hyperbaric oxygen at 1.5 ATA and Sham treatment in Persistent Post-concussive Syndrome and Concussion Post Syndrome, sponsored by Essentia Health. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Essentia Health · Phase 2, Interventional, and Treatment

How we know

Updated Oct 15, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Post-Concussion Syndrome with a site in United States — 15 open to participants now, 20 under way, 1 of them phase 3. Post-Concussion Syndrome · United States.

Enrollment
46th of 61
20 · median 40
Started
2022
with 1 other
Phase 2
14 of 77
5 open now
Registered
58th of 77
by date

Among the 77 studies in Post-Concussion Syndrome with a site in United States, this one is the 46th largest by enrollment of the 61 interventional ones that give a count, is one of 2 that started in 2022, is one of 14 in phase 2, and was the 58th registered.

Post-Concussion Syndrome

140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.

Browse Post-Concussion Syndrome studies →

Open to participants now

15 of the 77 studies in Post-Concussion Syndrome with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Post-Concussion Syndrome studies recruiting now, 3 (13%) set no upper age limit and 20 (83%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Post-Concussion Syndrome with a site in United States, or all of them as a file.
02

Study summary

Persistent post-concussive symptoms (PPCS) are a source of significant burden among a subset of patients with concussion with prevalence rates previously reported between 11 - 82% based on timing of assessment, diagnostic criteria, or population under study.

Examples of persistent post-concussion symptoms include balance problems, headaches, fatigue, poor concentration, forgetfulness, anxiety, irritability, and sleep disturbance. Few proposed therapies have proved successful in the management of persistent post-concussion symptoms following mild traumatic brain injury.

The investigators will explore hyperbaric oxygen administered in a randomized sham-controlled clinical trial as an effective and tolerable treatment in improving neuropsychological status among adult patients with persistent post-concussive symptoms.

The overall hypothesis to be evaluated is that hyperbaric oxygen improves neuropsychological status and a serum concussion biomarker associated with PPCS.

Read the detailed description

This is a parallel, randomized, double-blinded and sham-controlled study. A total of 100 subjects will be randomly assigned to either an intervention arm: 50 participants exposed to > 99.9% oxygen at 1.5 atmosphere absolute for 60 minutes over 40 treatments or sham-treatment arm: 50 participants exposed to oxygen and pressure composition equivalent to breathing atmospheric air for 60 minutes over 40 treatments.

This study is designed to determine whether hyperbaric oxygen improves neuropsychological status and ameliorates symptoms in adults with persistent post-concussive symptoms (PPCS) following mild traumatic brain injury. It recruits from either military or civilian population; uses a validated screening tool - Repeatable battery for the assessment of neuropsychological status (RBANS)- used in dementia and other forms of brain injury not used hitherto, in previous randomized control trial that investigated the effectiveness of hyperbaric oxygen in the management of PPCS. It also includes a concssuon biomarker, as an objective secondary endpoint.

The study is based on repeated measure design. The study will describe and track changes in the outcomes of interest over time, and examine associations between measures within each participant and across certain participant characteristics.

03

Conditions studied

  • Persistent Post-concussive Syndrome
  • Concussion Post Syndrome

Keywords

  • Hyperbaric oxygen treatment
  • Neurofilament light chain
  • RBANS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteers must have a history of mild traumatic brain injury, specifically, persistent post-concussive symptoms after examination by a neuropsychologist or neurologist.
  • Volunteers time from concussive incident (Mild traumatic brain injury) must be between 3 months - 5 years following head trauma incident
  • TBI was caused by non-penetrating trauma
  • Volunteers must have current complaints of TBI symptoms such as headache, dizziness, or cognitive or affective problems
  • Volunteers must be 18-year-old or more
  • Willing and able to provide
  • Able to speak and read English, as primary language
  • Agrees to provide blood samples for clinical lab tests
  • Willing and committed to comply with research protocol and complete all outcome measures
  • Able to equalize middle ear pressures or willing to undergo needle myringotomies if needed
  • Willingness and committed to comply with study protocol outlined reproductive plan based on baseline reproductive status

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with hyperbaric oxygen treatment
  • Hyperbaric chamber inside attendant, professional, SCUBA diver (technical, commercial, operational/military or recreational)
  • The investigators will exclude pregnant women from this study because potential fetal adverse reactions triggered by high oxygen partial pressures such as retrolenticular fibroplasia though careful review of human data are generally reassuring such as the use of hyperbaric oxygen to treat acute carbon monoxide poison in the pregnant patient.13
  • Prisoners
  • Minors
  • Unable to protect airway or requires frequent suctioning
  • Known or suspected peri-lymphatic fistula
  • Presence of tracheostomy (due to limitations in auto-inflating the middle ear)
  • Unable to participate fully in outcome assessments
  • Unable to cooperate with hyperbaric oxygen treatments
  • Unable to speak and read English, as primary language
  • Not cooperating with instructions during hyperbaric oxygen treatments such as bringing contraband items into the chamber (such as fire lighter)
  • Not competent to sign their own consent. Such potential participants will not have the capacity to participate in a full range of neurocognitive testing
  • Pre-existing diagnosis of a psychotic disorder(s): schizophrenia, bipolar, dissociative disorder
  • History of moderate or severe traumatic brain injury
  • History of brain injury not of traumatic etiology such as stroke or drug-induced coma
  • Verifiable diagnosis of learning disability. Other pre-existing cognitive issues may make it difficult for potential participants to fill out certain outcome assessments such as neurobehavioral symptomatic inventory. This could lead to measurement bias or confound the result.
  • Claustrophobia and unwilling to enter hyperbaric chamber
  • Untreated pneumothorax
  • Presence of implanted device with un-verifiable test to pressure by manufacturer
  • Concurrent enrollment in an alternate interventional trial for post concussive symptoms
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    HBO at 1.5 Atmosphere absolute

    Participants in this group will be exposed to hyperbaric oxygen at 1.5 atmosphere absolute (ATA) for 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization

    Drug: Hyperbaric oxygen at 1.5 ATA

  • Sham comparator
    Sham control initially at 1.2 then changed to 1.0 ATA

    Participants in this group will be exposed to hyperbaric oxygen at 1.2 atmosphere absolute (ATA) during the first 5 to 7 minutes and the chamber pressure will be reduced to 1.0 ATA for the remaining 53 - 57 minutes for a total of 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization

    Drug: Sham treatment

Interventions

  • DrugHyperbaric oxygen at 1.5 ATA

    Hyperbaric oxygen (HBO2) at 1.5 ATA (active) group (hyperbaric oxygen-chamber compressed to 1.5 atmosphere absolute and breathing \>99.9% oxygen). Each participant should complete 40 sessions, one session per day, five per week over the course of 3 months.

    Also known as: 1.5 ATA

  • DrugSham treatment

    Sham treatment includes pressurizing the chamber to 1.2 ATA with air for 5 minutes with noise of circulating air, return the chamber to 1.0 ATA after 5-7 minutes and maintain it at that pressure for until the end of the treatment, with noise of circulating air. Internal control knobs will be concealed. Participants will be instructed to undergo intermittent ear clearing technique during the initial 5 minutes of "descent"

    Also known as: 1.2 ATA then changed to 1.0 ATA

06

What researchers measure

Primary outcomes

  1. Changes in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    RBANS comprises 12 subtests that yield five age-adjusted Index scores, each measuring a distinct cognitive domain, plus a Total Scale score reflecting global cognitive functioning: Immediate Memory Index Visuospatial/Constructional Index Language Index Attention Index Delayed Memory Index Raw subtest scores are converted to age-normed standard scores, yielding five Index scores and a Total Scale score, each with a normative mean of 100, standard deviation of 15, and obtainable range of approximately 40 to 160. The Total Scale score is not a sum or average of the Index scores; the five Index scores are summed, and that sum is converted to a standard score on the same metric. For every Index and for the Total Scale score, higher values indicate better cognitive performance, and lower values indicate worse performance. All values reported are age-adjusted standard scores; the "3-12 Months" row is each participant's mean across the 13-week, 6-month, and 12-month assessments.

    Time frame: 13-week, 6-month, 12-month

Secondary outcomes

  1. Serum Concentrations of GFAP, NfL, Total Tau, and UCH-L1 at Baseline and 13 Weeks Post-Treatment

    Serum concentrations of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), total tau, and ubiquitin C-terminal hydrolase L1 (UCH-L1), quantified in a single batch using the Quanterix Simoa Neurology 4-Plex B assay. Laboratory personnel were blinded to treatment allocation.

    Time frame: Baseline, 13-week

  2. PSQI Global Score

    Description (components): Pittsburgh Sleep Quality Index component scores. Each of the seven components is scored 0-3; higher scores indicate worse sleep. C1 = subjective sleep quality; C2 = sleep latency; C3 = sleep duration; C4 = habitual sleep efficiency (hours slept ÷ hours in bed × 100); C5 = sleep disturbances; C6 = use of sleep medication; C7 = daytime dysfunction. Description (global): PSQI global score, the sum of all seven component scores. Range 0-21; higher scores indicate worse sleep quality. A global score \>5 indicates poor sleep quality.

    Time frame: Baseline, 13-week, 6-month, 12-month

  3. Neurobehavioral Symptom Inventory Total Score

    This is a validated self-report measure of post-concussion symptoms, grouped into 4 clusters (somatosensory, cognitive, affective, and vestibular). Neurobehavioral Symptom Inventory (NSI) is a 22-item symptom scale; participants will rate the severity of their symptoms in the last 2 weeks on a 5-point Likert scale (0=none, 1= mild, 2=moderate, 3=severe, 4=very severe). The NSI total score is a sum of the 22 items (range 0-88). Higher scores indicate more severe symptoms.

    Time frame: Baseline, 13 week, 6 month, 12 month

  4. PCL-C Total Score c(Civilian)

    This is a 17-item validated self-report measure that assesses PTSD symptoms. It is further subcategorized into three clusters (reexperiencing, avoidance, hyperarousal). A total score and cluster scores can be obtained based on DSM-IV-TR criteria. Each item is rated 1-5; total score ranges 17 to 85. Higher scores indicate worse symptom burden.

    Time frame: Baseline, 13 weeks, 6 months, 12 months

  5. WHOQOL-BREF Psychological Domain Score

    World Health Organization Quality of Life - BREF (WHOQOL-BREF), a 26-item self-report instrument yielding four domain scores. All four domain scores are transformed to a 0-100 scale. Higher scores indicate better quality of life. The psychological domain result is shown here.

    Time frame: Baseline, 13 weeks, 6 months, 12 months

07

Results

Posted Oct 15, 2026
Limitations and caveats
Low recruitment rate leading to a small number of participants.

Participant flow

Participants were recruited from outpatient clinics and hospitals in North Dakota. Candidates were referred to the neurology clinic at Essentia Health, Fargo, ND, where the study neurologist confirmed a diagnosis of persistent post-concussive symptoms following mild TBI and assessed eligibility. Candidates willing to participate underwent further assessment by hyperbaric research staff to fitness to receive hyperbaric exposure. Written informed consent was obtained before formal enrollment

Participant flow — Overall Study
MilestoneMild Hyperbaric Oxygen (Intervention)Placebo Comparator
Started911
Did not receive allocated intervention13
Completed88
Not completed13

Outcome measures

PrimaryChanges in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

RBANS comprises 12 subtests that yield five age-adjusted Index scores, each measuring a distinct cognitive domain, plus a Total Scale score reflecting global cognitive functioning: Immediate Memory Index Visuospatial/Constructional Index Language Index Attention Index Delayed Memory Index Raw subtest scores are converted to age-normed standard scores, yielding five Index scores and a Total Scale score, each with a normative mean of 100, standard deviation of 15, and obtainable range of approximately 40 to 160. The Total Scale score is not a sum or average of the Index scores; the five Index scores are summed, and that sum is converted to a standard score on the same metric. For every Index and for the Total Scale score, higher values indicate better cognitive performance, and lower values indicate worse performance. All values reported are age-adjusted standard scores; the "3-12 Months" row is each participant's mean across the 13-week, 6-month, and 12-month assessments.

Time frame:
13-week, 6-month, 12-month
Reported as:
Mean · Score on a scale
Changes in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Score on a scaleMild Hyperbaric Oxygen (Intervention)Placebo Control
Mean value of Immediate Memory assessed at 13-week, 6-month, and 12-month105.41 ± 18.0891.37 ± 17.16
Mean value of Visuospatial/Constructional assessed at 13-week, 6-month, and 12-month101.50 ± 12.32100.53 ± 15.70
Mean value of Language assessed at 13-week, 6-month, and 12-month100.55 ± 8.48100.26 ± 9.64
Mean value of Attention assessed at 13-week, 6-month, and 12-month102.05 ± 10.9796.89 ± 12.39
Mean value of Delayed Memory assessed at 13-week, 6-month, and 12-month102.00 ± 16.5096.47 ± 18.76
Mean value of Total RBANS score assessed at 13-week, 6-month, and 12-month101.59 ± 12.6098.11 ± 17.85
SecondarySerum Concentrations of GFAP, NfL, Total Tau, and UCH-L1 at Baseline and 13 Weeks Post-Treatment

Serum concentrations of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), total tau, and ubiquitin C-terminal hydrolase L1 (UCH-L1), quantified in a single batch using the Quanterix Simoa Neurology 4-Plex B assay. Laboratory personnel were blinded to treatment allocation.

Time frame:
Baseline, 13-week
Reported as:
Mean · pg/mL
Serum Concentrations of GFAP, NfL, Total Tau, and UCH-L1 at Baseline and 13 Weeks Post-Treatment
pg/mLMild Hyperbaric Oxygen (Intervention)Placebo Control
GFAP, Baseline21.69 ± 16.1410.19 ± 8.48
GFAP, 13 Weeks14.10 ± 7.298.88 ± 6.86
NfL, Baseline11.84 ± 7.838.54 ± 3.16
NfL, 13 weeks12.13 ± 9.1110.80 ± 8.42
Total Tau, Baseline1.47 ± 0.401.49 ± 0.70
Total Tau, 13 weeks1.58 ± 0.541.42 ± 0.88
UCH-L1, Baseline156.66 ± 153.05160.00 ± 44.01
UCH-L1, 13 weeks114.29 ± 85.97195.30 ± 155.23
SecondaryPSQI Global Score

Description (components): Pittsburgh Sleep Quality Index component scores. Each of the seven components is scored 0-3; higher scores indicate worse sleep. C1 = subjective sleep quality; C2 = sleep latency; C3 = sleep duration; C4 = habitual sleep efficiency (hours slept ÷ hours in bed × 100); C5 = sleep disturbances; C6 = use of sleep medication; C7 = daytime dysfunction. Description (global): PSQI global score, the sum of all seven component scores. Range 0-21; higher scores indicate worse sleep quality. A global score \>5 indicates poor sleep quality.

Time frame:
Baseline, 13-week, 6-month, 12-month
Reported as:
Mean · Score on a scale
PSQI Global Score
Score on a scaleMild Hyperbaric Oxygen (Intervention)Placebo Control
Baseline8.50 ± 2.6511.71 ± 3.15
13-week9.38 ± 2.678.67 ± 3.72
6-month10.50 ± 4.178.50 ± 1.64
12-month9.33 ± 3.569.50 ± 3.21
SecondaryNeurobehavioral Symptom Inventory Total Score

This is a validated self-report measure of post-concussion symptoms, grouped into 4 clusters (somatosensory, cognitive, affective, and vestibular). Neurobehavioral Symptom Inventory (NSI) is a 22-item symptom scale; participants will rate the severity of their symptoms in the last 2 weeks on a 5-point Likert scale (0=none, 1= mild, 2=moderate, 3=severe, 4=very severe). The NSI total score is a sum of the 22 items (range 0-88). Higher scores indicate more severe symptoms.

Time frame:
Baseline, 13 week, 6 month, 12 month
Reported as:
Mean · Score on a scale
Neurobehavioral Symptom Inventory Total Score
Score on a scaleMild Hyperbaric Oxygen (Intervention)Placebo Control
Baseline34.13 ± 17.5947.00 ± 12.18
13 weeks32.00 ± 14.1637.86 ± 17.70
6 months25.00 ± 12.0242.33 ± 15.19
12 months28.67 ± 9.0942.17 ± 16.94
SecondaryPCL-C Total Score c(Civilian)

This is a 17-item validated self-report measure that assesses PTSD symptoms. It is further subcategorized into three clusters (reexperiencing, avoidance, hyperarousal). A total score and cluster scores can be obtained based on DSM-IV-TR criteria. Each item is rated 1-5; total score ranges 17 to 85. Higher scores indicate worse symptom burden.

Time frame:
Baseline, 13 weeks, 6 months, 12 months
Reported as:
Mean · Score on a scale
PCL-C Total Score c(Civilian)
Score on a scaleMild Hyperbaric Oxygen (Intervention)Placebo Control
Baseline43.88 ± 17.6844.63 ± 13.23
13 weeks42.25 ± 17.1140.07 ± 13.37
6 months42.13 ± 22.3546.34 ± 11.28
12 months38.67 ± 18.4942.67 ± 13.47
SecondaryWHOQOL-BREF Psychological Domain Score

World Health Organization Quality of Life - BREF (WHOQOL-BREF), a 26-item self-report instrument yielding four domain scores. All four domain scores are transformed to a 0-100 scale. Higher scores indicate better quality of life. The psychological domain result is shown here.

Time frame:
Baseline, 13 weeks, 6 months, 12 months
Reported as:
Mean · Score on a scale
WHOQOL-BREF Psychological Domain Score
Score on a scaleMild Hyperbaric Oxygen (Intervention)Placebo Control
Baseline53.13 ± 14.9245.83 ± 18.23
13 weeks58.33 ± 15.6747.22 ± 16.44
6 months58.33 ± 17.2348.61 ± 15.89
12 months57.64 ± 12.4550.00 ± 15.22

Adverse events

Collected over From the first study intervention session, 40 sessions delivered on weekdays over approximately 8 weeks per participant, up to the final study assessment period at 18 months after completing the 40 sessions.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mild Hyperbaric Oxygen Treatment (Intervention)0/8 (0%)0/8 (0%)5/8 (62.5%)
Placebo Control0/8 (0%)0/8 (0%)2/8 (25%)
Most frequent other events
Most frequent other events
EventMild Hyperbaric Oxygen Treatment (Intervention)Placebo Control
Middle ear barotraumaEar and labyrinth disorders4/81/8
ClaustrophobiaGeneral disorders1/80/8
Progression of underlying conditionNervous system disorders1/81/8

Baseline characteristics

Baseline characteristics are reported for the 16 randomized participants who completed the baseline assessment and initiated their allocated study intervention. Four randomized participants (1 intervention, 3 placebo) did not receive the allocated intervention and did not contribute baseline data.

Age, Continuous
Age, Continuous(years)Mild Hyperbaric OxygenPlacebo ControlTotal
Mean48.88 ± 14.2942.13 ± 10.6045.50 ± 12.64
Sex: Female, Male
Sex: Female, Male(Participants)Mild Hyperbaric OxygenPlacebo ControlTotal
Female7613
Male123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Mild Hyperbaric OxygenPlacebo ControlTotal
Race: White8816
Region of Enrollment
Region of Enrollment(Participants)Mild Hyperbaric OxygenPlacebo ControlTotal
United States8816
Time from injury
Time from injury(months)Mild Hyperbaric OxygenPlacebo ControlTotal
Mean20.63 ± 14.0315.13 ± 10.0317.88 ± 12.12
08

Study locations

1 site
  • Essentia Health
    Fargo, North Dakota 58103, United States
09

References and documents

Publications

  • Moser RS, Schatz P. Enduring effects of concussion in youth athletes. Arch Clin Neuropsychol. 2002 Jan;17(1):91-100. PubMed 14589756 ↗
  • Shahim P, Politis A, van der Merwe A, Moore B, Chou YY, Pham DL, Butman JA, Diaz-Arrastia R, Gill JM, Brody DL, Zetterberg H, Blennow K, Chan L. Neurofilament light as a biomarker in traumatic brain injury. Neurology. 2020 Aug 11;95(6):e610-e622. doi: 10.1212/WNL.0000000000009983. Epub 2020 Jul 8. PubMed 32641538 ↗
  • Cook PA, Johnson TM, Martin SG, Gehrman PR, Bhatnagar S, Gee JC. A Retrospective Study of Predictors of Return to Duty versus Medical Retirement in an Active Duty Military Population with Blast-Related Mild Traumatic Brain Injury. J Neurotrauma. 2018 Apr 15;35(8):991-1002. doi: 10.1089/neu.2017.5141. Epub 2018 Mar 1. PubMed 29239267 ↗
  • Weaver LK, Wilson SH, Lindblad AS, Churchill S, Deru K, Price RC, Williams CS, Orrison WW, Walker JM, Meehan A, Mirow S. Hyperbaric oxygen for post-concussive symptoms in United States military service members: a randomized clinical trial. Undersea Hyperb Med. 2018 Mar-Apr;45(2):129-156. PubMed 29734566 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The study protocol, statistical plan and consent form will be available on request. Data will be available on aggregate level; data will be deidentified, the full dataset and statistical code will be available upon request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: 6 months after study completion and for 36 months

Access criteria: A full description of the intended use of the data must be sent to the corresponding author for review and approval. Participant consent for data sharing is conditioned and new ethics approval may be required.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Aug 2025, 37 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2021
First posted
Dec 30, 2021
StartActual
Jun 28, 2022
Primary completionActual
Aug 1, 2025
CompletionActual
Aug 1, 2025
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChanges in Repeatable batteryBattery for the assessmentAssessment of neuropsychological statusNeuropsychological Status (RBANS)Time frame: Baseline, 1-week, 13-week, 18-month → 13-week, 6-month, 12-month
Oct 15, 2026
Documents
Secondary outcomes
5 added, 5 removed
What changed in the outcomes
  • AddedSerum Concentrations of GFAP, NfL, Total Tau, and UCH-L1 at Baseline and 13 Weeks Post-TreatmentTime frame: Baseline, 13-week
  • AddedPSQI Global ScoreTime frame: Baseline, 13-week, 6-month, 12-month
  • AddedNeurobehavioral Symptom Inventory Total ScoreTime frame: Baseline, 13 week, 6 month, 12 month
  • AddedPCL-C Total Score c(Civilian)Time frame: Baseline, 13 weeks, 6 months, 12 months
  • AddedWHOQOL-BREF Psychological Domain ScoreTime frame: Baseline, 13 weeks, 6 months, 12 months
  • RemovedChanges in serum Neurofilament Light chain (NfL) levelTime frame: Baseline, 1-week, 13-week, 18-month
  • RemovedChanges in Pittsburg Sleep Quality Index (PSQI) scoreTime frame: Baseline, 1-week, 13-week, 18-month
  • RemovedChanges in Neurobehavioral Symptom Inventory (NSI) scoresTime frame: Baseline, 1-week, 13-week, 18-month
  • RemovedChanges in reported PTSD-Civilian version (PCL-C) measuresTime frame: Baseline, 1-week, 13-week, 18-month
  • RemovedChanges in World Health Organization Quality of Life -BREF (WHOQOL-BREF) domain scoresTime frame: Baseline, 1-week, 13-week, 18-month
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChanges in Repeatable batteryBattery for the assessmentAssessment of neuropsychological statusNeuropsychological Status (RBANS)Time frame: Baseline, 1-week, 13-week, 18-month → 13-week, 6-month, 12-month
    Secondary outcomes 5 added, 5 removed
    What changed in the outcomes
    • AddedSerum Concentrations of GFAP, NfL, Total Tau, and UCH-L1 at Baseline and 13 Weeks Post-TreatmentTime frame: Baseline, 13-week
    • AddedPSQI Global ScoreTime frame: Baseline, 13-week, 6-month, 12-month
    • AddedNeurobehavioral Symptom Inventory Total ScoreTime frame: Baseline, 13 week, 6 month, 12 month
    • AddedPCL-C Total Score c(Civilian)Time frame: Baseline, 13 weeks, 6 months, 12 months
    • AddedWHOQOL-BREF Psychological Domain ScoreTime frame: Baseline, 13 weeks, 6 months, 12 months
    • RemovedChanges in serum Neurofilament Light chain (NfL) levelTime frame: Baseline, 1-week, 13-week, 18-month
    • RemovedChanges in Pittsburg Sleep Quality Index (PSQI) scoreTime frame: Baseline, 1-week, 13-week, 18-month
    • RemovedChanges in Neurobehavioral Symptom Inventory (NSI) scoresTime frame: Baseline, 1-week, 13-week, 18-month
    • RemovedChanges in reported PTSD-Civilian version (PCL-C) measuresTime frame: Baseline, 1-week, 13-week, 18-month
    • RemovedChanges in World Health Organization Quality of Life -BREF (WHOQOL-BREF) domain scoresTime frame: Baseline, 1-week, 13-week, 18-month
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05173818
Lead sponsor
Essentia Health
Collaborators
University of North Dakota, Dakota Medical Foundation, The Swanson Foundation, State of North Dakota
Responsible party
Sponsor
First posted
Dec 30, 2021
Start date
Jun 28, 2022
Primary completion
Aug 1, 2025
Completion
Aug 1, 2025
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Olayinka D Ajayi, MD, MPH
principal investigator · Essentia Health
Marc Basson, MD, PhD
principal investigator · University of North Dakota
Marilyn Klug, PhD
study chair · University of North Dakota
Paulina Kunecka, MD
study chair · Essentia Health
Richard Ferraro, PhD
study chair · University of North Dakota
Rebecca Quinn, MSW, LMSW
study chair · Center for Rural Health, University of North Dakota
Sharon Hanson, RN
study director · Essentia Health

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion